Literature DB >> 34035748

Clinical Implications of Recent Findings From the EVOLVE Study.

Brian Bressler1.   

Abstract

Year:  2020        PMID： 34035748      PMCID： PMC8132657     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  1 in total

1.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Authors:  Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245
  1 in total
  1 in total

1.  Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab.

Authors:  Charles Miller; Hanson Kwok; Paul Harrow; Roser Vega; Edward Seward; Shameer Mehta; Farooq Rahman; Sara McCartney; Ioanna Parisi; Samuel Hsiang Lim; Esha Sharma; Mark A Samaan; Aaron Bancil; Klaartje Bel Kok; Ahmed Shalabi; Emma L Johnston; Dev Katarey; Nina Taherzadeh; Charles Murray; Mohammed Tauseef Sharip; Martyn J Carter; Shiva T Radhakrishnan; Simon Peake; Imran Khakoo; Mahmood Wahed; Sebastian Povlsen; Mehul Patel; Patrick DuBois; Jemima Finkel; Clive Onnie; Stuart Bloom
Journal:  Frontline Gastroenterol       Date:  2022-01-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.